DC Business DC
Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blo…
